Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04664634 · ClinicalTrials.gov registry record · Phase 3
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
A Phase 3 study of Parkinson Disease and Dysphagia, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT04664634 is a Phase 3 study of Parkinson Disease and Dysphagia that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04664634, a Phase 3 study of Parkinson Disease and Dysphagia, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
Conditions Studied
Interventions
- DEVICE Aria Sensor
Study Locations (1)
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04664634
The ClinicalTrials.gov registry entry for NCT04664634 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Aria Sensor is the first listed.
NCT04664634 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04664634 about?
NCT04664634 is a clinical study titled "A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's". The purpose of this study is the development and early-stage validation of a wearable sensor for dysphagia in patients with PD.
What is the current status of trial NCT04664634?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-04-01. Estimated completion is 2026-05-31.
What conditions does trial NCT04664634 study?
This clinical trial studies the following conditions: Parkinson Disease, Dysphagia.
What interventions are being tested in trial NCT04664634?
The interventions under investigation include: Aria Sensor (DEVICE).
Who is sponsoring clinical trial NCT04664634?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04664634 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.